by qfrsolutions | Apr 12, 2017 | News
Source: LinkedIn I’m sure you’ve been asked many times whether you’re an introvert or an extrovert. For some people, it’s an easy choice, but for most of us, it’s difficult to choose one way or the other. It’s hard to choose because the introvert/extrovert dichotomy...
by qfrsolutions | Mar 27, 2017 | News
Source: FierceBiotech Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two...
by qfrsolutions | Mar 21, 2017 | News
Source: Cipher Pharmaceuticals Inc. (CPH.TO) (“Cipher” or “the Company”) announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief Executive Officer of Cipher, effective April 17 ,...
by qfrsolutions | Mar 17, 2017 | News
Source: Sun Pharmaceutical Industries today said an indirect arm of its group firm Taro will fully acquire Canada’s Thallion Pharmaceuticals for 2.7 million Canadian dollar. Taro Pharmaceuticals Inc (Canada) has entered into an agreement to acquire all of the...
by qfrsolutions | Mar 6, 2017 | News
Source: Novan MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302 pivotal clinical trials for the Company’s topical...
by qfrsolutions | Feb 13, 2017 | News
Source: Since its massive Pfizer merger fell through last year, Allergan has persisted with “stepping-stone deals” rather than a transformational buy. Monday, the drugmaker unveiled its latest buy, Zeltiq, a $2.47 billion add-on for its aesthetics...
